H. Robert Brashear
About
H. Robert Brashear is a scholar working on Psychiatry and Mental health, Physiology and Neurology.
According to data from OpenAlex, H. Robert Brashear has authored 86 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Psychiatry and Mental health, 35 papers in Physiology and 25 papers in Neurology. Recurrent topics in H. Robert Brashear's work include Alzheimer's disease research and treatments (31 papers), Dementia and Cognitive Impairment Research (30 papers) and Autoimmune Neurological Disorders and Treatments (13 papers). H. Robert Brashear is often cited by papers focused on Alzheimer's disease research and treatments (31 papers), Dementia and Cognitive Impairment Research (30 papers) and Autoimmune Neurological Disorders and Treatments (13 papers). H. Robert Brashear collaborates with scholars based in United States, Belgium and United Kingdom. H. Robert Brashear's co-authors include John Greenlee, Lennart Heimer, László Záborszky, Jørn Carlsen, Reisa A. Sperling, Howard Feldman, Ronald S. Black, Michael Grundman, Philip Scheltens and Stephen Salloway and has published in prestigious journals such as The Journal of Immunology, Neurology and Journal of Bone and Joint Surgery.
In The Last Decade
H. Robert Brashear
86 papers receiving 3.7k citations
Hit Papers
Peers
H. Robert Brashear
Dushyant P. Purohit United States
Debby W. Tsuang United States
Thomas Leyhe Germany
William S. Brooks Australia
Douglas Galasko United States
Eric E. Abrahamson United States
Mirosław Bryś United States
M. Axel Wollmer Germany
Rajesh N. Kalaria United States
Xiaoyan Sun United States
Citations per year, relative to H. Robert Brashear H. Robert Brashear (= 1×)
peers
Dushyant P. Purohit
Countries citing papers authored by H. Robert Brashear
Since
Specialization
Citations
This map shows the geographic impact of H. Robert Brashear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Robert Brashear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Robert Brashear more than expected).
Fields of papers citing papers by H. Robert Brashear
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by H. Robert Brashear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Robert Brashear. The network helps show where H. Robert Brashear may publish in the future.
Co-authorship network of co-authors of H. Robert Brashear
This figure shows the co-authorship network connecting the top 25 collaborators of H. Robert Brashear. A scholar is included among the top collaborators of H. Robert Brashear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Robert Brashear. H. Robert Brashear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grill, Joshua D., Rema Raman, Karin Ernström, et al.. (2024). Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurology Clinical Practice. 14(2). e200265–e200265.
2.
Greenlee, John & H. Robert Brashear. (2022). The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease. The Cerebellum. 22(4). 531–533.
3.
Papp, Kathryn V., Hany Rofael, Amy E. Veroff, et al.. (2022). Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. The Journal of Prevention of Alzheimer s Disease. 9(2). 255–261.
4.
Novak, Gerald, Johannes Streffer, Maarten Timmers, et al.. (2020). Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer s Research & Therapy. 12(1).
5.
Harrison, Jayne, et al.. (2018). Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study. The Journal of Prevention of Alzheimer s Disease. 5(4). 236–244.
6.
Delnomdedieu, Marielle, Sridhar Duvvuri, Nazem Atassi, et al.. (2016). First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 8(1). 12–12.
7.
Ivanoiu, Adrian, Jérémie Pariente, Kevin Booth, et al.. (2016). Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. Alzheimer s Research & Therapy. 8(1). 24–24.
8.
Häger, Klaus, et al.. (2016). Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer s Research & Therapy. 8(1). 47–47.
9.
Ketter, Nzeera, Di Jiang, Lawrence S. Honig, et al.. (2016). A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE. The Journal of Prevention of Alzheimer s Disease. 3(4). 1–10.
10.
Arrighi, H. Michael, Jerome Barakos, Frederik Barkhof, et al.. (2015). Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. Journal of Neurology Neurosurgery & Psychiatry. 87(1). jnnp–2014.
11.
Sperling, Reisa A., Stephen Salloway, David J. Brooks, et al.. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. The Lancet Neurology. 11(3). 241–249.
12.
Sperling, Reisa A., Clifford R. Jack, Sandra E. Black, et al.. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer s & Dementia. 7(4). 367–385.
13.
Feldman, Howard, Tuula Pirttilä, Jean‐François Dartigues, et al.. (2008). Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurologica Scandinavica. 119(1). 22–31.
14.
Korf, Esther S.C., Wiesje M. van der Flier, H. Robert Brashear, et al.. (2007). Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. Archives of Neurology. 64(7). 1023–1023.
15.
Brashear, H. Robert. (2003). Galantamine in the Treatment of Vascular Dementia. International Psychogeriatrics. 15. 187–193.
16.
Abraham, Ivo L., et al.. (1994). Cognitive Screening of Nursing Home Residents: Factor Structures of the Mini‐Mental State Examination. Journal of the American Geriatrics Society. 42(7). 750–756.
17.
Vieweg, W. V. R., et al.. (1993). Frontal Release Signs and Their Relationship With the Initiation and Perseveration Component of the Mattis Dementia Rating Scale in Persons With Dementia. American Journal of Geriatric Psychiatry. 1(4). 310–315.
18.
Greenlee, John, et al.. (1992). Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up.. PubMed Central. 156(2). 199–202.
19.
Abraham, Ivo L., et al.. (1990). A psychogeriatric nursing assessment protocol for use in multidisciplinary practice. Archives of Psychiatric Nursing. 4(4). 242–259.
20.
Greenlee, John, H. Robert Brashear, & Robert M. Herndon. (1988). Immunoperoxidase Labeling of Rat Brain Sections with Sera from Patients with Paraneoplastic Cerebellar Degeneration and Systemic Neoplasia. Journal of Neuropathology & Experimental Neurology. 47(5). 561–571.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dushyant P. Purohit Breakdown of academic impact, for papers by Debby W. Tsuang Breakdown of academic impact, for papers by Thomas Leyhe Breakdown of academic impact, for papers by William S. Brooks Breakdown of academic impact, for papers by Douglas Galasko Breakdown of academic impact, for papers by Eric E. Abrahamson Breakdown of academic impact, for papers by Mirosław Bryś Breakdown of academic impact, for papers by M. Axel Wollmer Breakdown of academic impact, for papers by Rajesh N. Kalaria Breakdown of academic impact, for papers by Xiaoyan Sun